交易 Inozyme Pharma, Inc. - INZY CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.024068% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.001846% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|
Inozyme Pharma, Inc. Events
時間(協調世界時) (UTC) | 國家 | 事件 |
---|---|---|
No events scheduled |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 |
总营业费用 | 56.646 | 57.041 | 20.806 | 11.593 |
销售/一般/行政费用,总计 | 18.926 | 10.548 | 4.586 | 3.494 |
研究与开发 | 37.72 | 46.493 | 16.22 | 8.099 |
营业收入 | -56.646 | -57.041 | -20.806 | -11.593 |
利息收入(费用),非经营净值 | 0.211 | 0.37 | 1.106 | 0.284 |
其他,净值 | -0.189 | 0.247 | -0.024 | 4.345 |
税前净收入 | -56.624 | -56.424 | -19.724 | -6.964 |
税后净收入 | -56.624 | -56.424 | -19.724 | -6.964 |
未计算非常项目前的净收益 | -56.624 | -56.424 | -19.724 | -6.964 |
净收入 | -56.624 | -56.424 | -19.724 | -6.964 |
普通股股东可获收益 (不含非经常性项目) | -56.624 | -56.424 | -19.724 | -6.964 |
普通股股东可获收益 (含非經常性項目) | -56.624 | -56.424 | -19.724 | -6.964 |
摊薄净收入 | -56.624 | -56.424 | -19.724 | -6.964 |
摊薄后加权平均股 | 23.5583 | 11.0365 | 20.3148 | 20.3148 |
扣除特别项目的每股摊薄盈利 | -2.40357 | -5.11249 | -0.97092 | -0.3428 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
每股正常摊薄盈利 | -2.40357 | -5.11249 | -0.97092 | -0.3428 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 16.839 | 18.757 | 14.262 | 12.655 | 10.972 |
销售/一般/行政费用,总计 | 5.025 | 5.206 | 4.916 | 4.435 | 4.369 |
研究与开发 | 11.814 | 13.551 | 9.346 | 8.22 | 6.603 |
营业收入 | -16.839 | -18.757 | -14.262 | -12.655 | -10.972 |
利息收入(费用),非经营净值 | 0.06 | 0.043 | 0.047 | 0.058 | 0.063 |
其他,净值 | -0.105 | -0.04 | -0.065 | 0.057 | -0.141 |
税前净收入 | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
税后净收入 | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
未计算非常项目前的净收益 | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
净收入 | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
普通股股东可获收益 (不含非经常性项目) | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
普通股股东可获收益 (含非經常性項目) | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
摊薄净收入 | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
摊薄后加权平均股 | 23.6863 | 23.6673 | 23.6435 | 23.4906 | 23.4295 |
扣除特别项目的每股摊薄盈利 | -0.71282 | -0.7924 | -0.60397 | -0.53383 | -0.47163 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.71282 | -0.7924 | -0.60397 | -0.53383 | -0.47163 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
流动资产总额 | 115.342 | 150.979 | 47.46 | 43.267 |
现金和短期投资 | 111.801 | 147.697 | 47.132 | 43.163 |
现金等价物 | 23.316 | 28.04 | 31.605 | 35.966 |
短期投资 | 88.485 | 119.657 | 15.527 | 7.197 |
应收账款总额,净额 | 0.062 | 0.155 | 0.104 | 0.031 |
Prepaid Expenses | 3.479 | 3.127 | 0.224 | 0.073 |
Total Assets | 123.541 | 169.363 | 47.944 | 43.543 |
Property/Plant/Equipment, Total - Net | 4.436 | 2.648 | 0.298 | 0.242 |
Property/Plant/Equipment, Total - Gross | 5.437 | 2.975 | 0.408 | 0.269 |
Accumulated Depreciation, Total | -1.001 | -0.327 | -0.11 | -0.027 |
Other Long Term Assets, Total | 3.763 | 3.537 | 0.186 | 0.034 |
Total Current Liabilities | 11.633 | 9.973 | 3.236 | 2.389 |
Accounts Payable | 2.394 | 3.069 | 0.901 | 0.984 |
Accrued Expenses | 9.239 | 6.625 | 2.335 | 1.405 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Total Liabilities | 14.273 | 11.26 | 3.236 | 2.389 |
Total Long Term Debt | 0 | 0 | 0 | 0 |
Total Equity | 109.268 | 158.103 | 44.708 | 41.154 |
Preferred Stock - Non Redeemable, Net | 77.927 | 55.029 | ||
Common Stock | 0.002 | 0.002 | 0.001 | 0.001 |
Additional Paid-In Capital | 256.948 | 249.175 | 1.427 | 1.054 |
Retained Earnings (Accumulated Deficit) | -147.7 | -91.076 | -34.652 | -14.928 |
Other Equity, Total | 0.018 | 0.002 | 0.005 | -0.002 |
Total Liabilities & Shareholders’ Equity | 123.541 | 169.363 | 47.944 | 43.543 |
Total Common Shares Outstanding | 23.6726 | 23.385 | 20.3148 | 20.3148 |
Total Preferred Shares Outstanding | 72.4164 | |||
Long Term Investments | 0 | 12.199 | ||
Other Current Liabilities, Total | 0 | 0.279 | ||
Other Liabilities, Total | 2.64 | 1.287 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
流动资产总额 | 100.583 | 115.342 | 130.579 | 140.962 | 148.041 |
现金和短期投资 | 97.773 | 111.801 | 125.283 | 137.464 | 145.086 |
现金等价物 | 31.943 | 23.316 | 27.229 | 26.239 | 16.486 |
短期投资 | 65.83 | 88.485 | 98.054 | 111.225 | 128.6 |
应收账款总额,净额 | 0.048 | 0.062 | 0.073 | 0.095 | 0.122 |
Prepaid Expenses | 2.762 | 3.479 | 5.223 | 3.403 | 2.833 |
Total Assets | 108.931 | 123.541 | 137.746 | 148.259 | 158.915 |
Property/Plant/Equipment, Total - Net | 4.184 | 4.436 | 4.743 | 4.859 | 5.029 |
Property/Plant/Equipment, Total - Gross | 5.363 | 5.437 | 5.562 | 5.511 | 5.514 |
Accumulated Depreciation, Total | -1.179 | -1.001 | -0.819 | -0.652 | -0.485 |
Long Term Investments | 0 | 0 | 0 | 2.548 | |
Other Long Term Assets, Total | 4.164 | 3.763 | 2.424 | 2.438 | 3.297 |
Total Current Liabilities | 12.26 | 11.633 | 8.943 | 6.972 | 6.832 |
Accounts Payable | 2.2 | 2.394 | 0.626 | 0.796 | 1.709 |
Accrued Expenses | 10.06 | 9.239 | 8.317 | 6.176 | 5.123 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14.702 | 14.273 | 11.772 | 9.985 | 10.026 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 2.442 | 2.64 | 2.829 | 3.013 | 3.194 |
Total Equity | 94.229 | 109.268 | 125.974 | 138.274 | 148.889 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 258.94 | 256.948 | 254.915 | 252.92 | 251.001 |
Retained Earnings (Accumulated Deficit) | -164.584 | -147.7 | -128.946 | -114.666 | -102.126 |
Other Equity, Total | -0.129 | 0.018 | 0.003 | 0.018 | 0.012 |
Total Liabilities & Shareholders’ Equity | 108.931 | 123.541 | 137.746 | 148.259 | 158.915 |
Total Common Shares Outstanding | 23.8184 | 23.6726 | 23.6647 | 23.5706 | 23.4737 |
Other Current Liabilities, Total | 0 | 0 | 0 | ||
Preferred Stock - Non Redeemable, Net | 0 | 0 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
净收入/起跑线 | -56.624 | -56.424 | -19.724 | -6.964 |
经营活动产生的现金 | -48.153 | -35.974 | -18.81 | -9.437 |
经营活动产生的现金 | 0.674 | 0.217 | 0.083 | 0.026 |
非现金物品 | 7.712 | 20.344 | 0.23 | -3.93 |
营运资金的变化 | 0.085 | -0.111 | 0.601 | 1.431 |
投资活动产生的现金 | 42.796 | -117.179 | -8.391 | 9.006 |
资本支出 | -0.397 | -0.568 | -0.139 | -0.259 |
其他投资现金流量项目,总计 | 43.193 | -116.611 | -8.252 | 9.265 |
融资活动产生的现金 | 0.609 | 149.812 | 22.97 | 31.945 |
股票的发行(报废),净额 | 0.609 | 149.812 | 22.97 | 31.945 |
现金净变化 | -4.724 | -3.341 | -4.231 | 31.514 |
外汇效应 | 0.024 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -16.884 | -56.624 | -37.87 | -23.59 | -11.05 |
Cash From Operating Activities | -14.16 | -48.153 | -34.709 | -22.409 | -12.376 |
Cash From Operating Activities | 0.178 | 0.674 | 0.492 | 0.325 | 0.158 |
Non-Cash Items | 1.779 | 7.712 | 5.567 | 3.689 | 1.725 |
Changes in Working Capital | 0.767 | 0.085 | -2.898 | -2.833 | -3.209 |
Cash From Investing Activities | 22.562 | 42.796 | 33.309 | 20.247 | 0.573 |
Capital Expenditures | -0.017 | -0.397 | -0.357 | -0.278 | -0.088 |
Other Investing Cash Flow Items, Total | 22.579 | 43.193 | 33.666 | 20.525 | 0.661 |
Cash From Financing Activities | 0.24 | 0.609 | 0.598 | 0.361 | 0.249 |
Issuance (Retirement) of Stock, Net | 0.24 | 0.609 | 0.598 | 0.361 | 0.249 |
Net Change in Cash | 8.627 | -4.724 | -0.811 | -1.801 | -11.554 |
Foreign Exchange Effects | -0.015 | 0.024 | -0.009 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Longitude Capital Management Co., LLC | Venture Capital | 10.3341 | 4174379 | 1355000 | 2022-04-19 | LOW |
Sofinnova Investments, Inc | Venture Capital | 9.0491 | 3655308 | 0 | 2022-12-31 | MED |
Deep Track Capital LP | Hedge Fund | 8.0457 | 3250000 | 0 | 2022-12-31 | MED |
Adage Capital Management, L.P. | Hedge Fund | 7.6747 | 3100138 | 503466 | 2022-12-31 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 7.6397 | 3086027 | 278409 | 2022-12-31 | LOW |
VR Adviser, LLC | Venture Capital | 6.7088 | 2709987 | 0 | 2022-12-31 | MED |
Pivotal Bioventure Partners Investment Advisor LLC | Investment Advisor | 6.5879 | 2661154 | 0 | 2022-12-31 | LOW |
New Enterprise Associates (NEA) | Venture Capital | 6.0347 | 2437689 | -6690 | 2022-12-31 | LOW |
Cowen Investment Management LLC | Investment Advisor/Hedge Fund | 5.4584 | 2204876 | 208599 | 2022-12-31 | MED |
Sphera Funds Management Ltd. | Hedge Fund | 5.1895 | 2096258 | 471200 | 2023-03-03 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.3263 | 1343622 | 559 | 2022-12-31 | LOW |
Affinity Asset Advisors LLC | Hedge Fund | 1.2378 | 500000 | 500000 | 2022-12-31 | HIGH |
Millennium Management LLC | Hedge Fund | 0.7376 | 297936 | 127752 | 2022-12-31 | HIGH |
Laurion Capital Management LP | Hedge Fund | 0.6729 | 271800 | 0 | 2022-12-31 | HIGH |
Bolte (Axel) | Individual Investor | 0.6483 | 261890 | 3315 | 2022-09-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.6409 | 258900 | 103500 | 2022-12-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6362 | 256970 | -1351 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5771 | 233126 | -559 | 2022-12-31 | LOW |
BioImpact Capital LLC | Investment Advisor/Hedge Fund | 0.5706 | 230500 | -430644 | 2022-12-31 | LOW |
Overbrook Management Corporation | Investment Advisor | 0.543 | 219326 | 150000 | 2022-12-31 | LOW |
交易計算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Inozyme Pharma, Inc. Company profile
关于 Inozyme Pharma Inc.
Inozyme Pharma, Inc.是一家处于临床阶段的罕见疾病生物制药公司。 该公司专注于开发治疗影响血管、软组织和骨骼的异常矿化疾病的疗法。 该公司还专注于开发一种治疗罕见遗传病的疗法,即八核苷酸焦磷酸酶/磷酸二酯酶1(ENPP1)和ATP结合盒亚家族C成员6(ABCC6)的缺陷。 公司的主要候选产品INZ-701是一种可溶性、重组或基因工程的融合蛋白,旨在纠正ENPP1和ABCC6缺陷引起的矿化途径的缺陷。
Industry: | Biotechnology & Medical Research (NEC) |
321 Summer Street
Suite 400
BOSTON
MASSACHUSETTS 02210
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球500,000万多名交易者的一份子,选择利用Capital.com进行交易吧。